The inositol pyrophosphate pathway in health and diseases
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Inositol pyrophosphates (IPPs) are present in organisms ranging from plants, slime moulds and fungi to mammals. Distinct classes of kinases generate different forms of energetic diphosphate‐containing IPPs from inositol phosphates (IPs). Conversely, polyphosphate phosphohydrolase enzymes dephosphorylate IPPs to regenerate the respective IPs. IPPs and/or their metabolizing enzymes regulate various cell biological processes by modulating many proteins via diverse mechanisms. In the last decade, extensive research has been conducted in mammalian systems, particularly in knockout mouse models of relevant enzymes. Results obtained from these studies suggest impacts of the IPP pathway on organ development, especially of brain and testis. Conversely, deletion of specific enzymes in the pathway protects mice from various diseases such as diet‐induced obesity (DIO), type‐2 diabetes (T2D), fatty liver, bacterial infection, thromboembolism, cancer metastasis and aging. Furthermore, pharmacological inhibition of the same class of enzymes in mice validates the therapeutic importance of this pathway in cardio‐metabolic diseases. This review critically analyses these findings and summarizes the significance of the IPP pathway in mammalian health and diseases. It also evaluates benefits and risks of targeting this pathway in disease therapies. Finally, future directions of mammalian IPP research are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The versatility and universality of calcium signalling
Berridge, M. J., Lipp, P., & Bootman, M. D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036035 · Cited by 5,701
Linking DNA methylation and histone modification: patterns and paradigms
Cedar, H., & Bergman, Y. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2540 · Cited by 2,267 · cited 1×
“DNA methylation leads to long-term gene repression (Cedar & Bergman, 2009; Rose & Klose, 2014).”
BackgroundA quantitative atlas of mitotic phosphorylation
Dephoure, N., Zhou, C., Villén, J., Beausoleil, S. A., Bakalarski, C. E., Elledge, S. J., & Gygi, S. P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805139105 · Cited by 1,608
Mechanisms of specificity in protein phosphorylation
Ubersax, J. A., & Ferrell Jr, J. E. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2203 · Cited by 1,451
The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging
Kennedy, B. K., & Lamming, D. W. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.009 · Cited by 544
Saiardi, A., Erdjument-Bromage, H., Snowman, A. M., Tempst, P., & Snyder, S. H. (1999) · Current Biology · doi:10.1016/s0960-9822(00)80055-x · Cited by 414
Pleckstrin homology (PH) domains and phosphoinositides
Lemmon, M. A. (2007) · Biochemical Society Symposium · doi:10.1042/bss0740081 · Cited by 298 · cited 2×
“PH-domains in proteins bind phosphoinositides (Lemmon, 2007).”
BackgroundInositol pyrophosphates: between signalling and metabolism
Wilson, M. S. C., Livermore, T. M., & Saiardi, A. (2013) · Biochemical Journal · doi:10.1042/bj20130118 · Cited by 256
Inositol Pyrophosphates as Mammalian Cell Signals
Chakraborty, A., Kim, S., & Snyder, S. H. (2011) · Science Signaling · doi:10.1126/scisignal.2001958 · Cited by 160 · cited 19×
“Similarly, an apoptotic dose of the casein kinase-2 (CK2) inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB, 50 μM, 16 h) enhances IP7 level in IP6K2-overexpressing osteosarcoma (U2OS) cells (Chakraborty et al., 2011), whereas a lower dose (10 μM, 30 min) reduces IP7 levels and ATP/ADP ratio in IP6K1-predominated HIT-T15…”
BackgroundMethodSelf-citation
Cited by
Insulin Signal Transduction Perturbations in Insulin Resistance
Khalid, M., Alkaabi, J., Khan, M. A. B., & Adem, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168590 · Cited by 233
“The inositol phosphate, specifically inositol pyrophosphate IP7 generated by inositol-hexakisphosphate (IP6) kinase 1 (IP6K1), directly by its binding to the PH domain of Akt competes for PIP3 binding to Akt [64].”
BackgroundThe Inositol Phosphate Signalling Network in Physiology and Disease
Kim, S., Bhandari, R., Brearley, C. A., & Saiardi, A. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.08.005 · Cited by 70
Gu, C., Stashko, M. A., Puhl-Rubio, A. C., Chakraborty, M., Chakraborty, A., Frye, S. V., Pearce, K. H., Wang, X., Shears, S. B., & Wang, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01593 · Cited by 56
Self-citationLee, S., Beon, J., Kim, M.-G., & Kim, S. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2020 · Cited by 9
Aguirre, T., Dornan, G. L., Hostachy, S., Neuenschwander, M., Seyffarth, C., Haucke, V., Schütz, A., von Kries, J. P., & Fiedler, D. (2023) · eLife · doi:10.7554/elife.88982.3
Metadata
- Authors
- Chakraborty, A.
- Venue
- Biological Reviews
- Publisher
- Wiley
- Published
- 2017-12-27
- Volume
- 93
- Issue
- 2
- Pages
- 1203-1227
- ISSN
- 0006-3231 (ISSN-L)
- 1464-7931
- 1469-185X
- OpenAlex
- W2907201154
- Cited by
- 113
- References
- 9
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The inositol pyrophosphate pathway in health and diseases. https://app.cochat.ai/papers/10.1111/brv.12392
- The paper
- Chakraborty, A. (2018). The inositol pyrophosphate pathway in health and diseases. Biological Reviews. https://doi.org/10.1111/brv.12392
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.